

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 June 2006 (29.06.2006)

PCT

(10) International Publication Number
WO 2006/068953 A3

(51) International Patent Classification:

C07K 16/22 (2006.01) C12N 15/13 (2006.01)
C07K 16/28 (2006.01) C12N 15/85 (2006.01)

(74) Agent: COOLEY GODWARD KRONISH LLP; Attn:
Patent Group, 1200 19th Street, NW, Suite 500, Washing-
ton, DC 20036-2412 (US).

(21) International Application Number:

PCT/US2005/045657

(22) International Filing Date:

19 December 2005 (19.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/638,354 21 December 2004 (21.12.2004) US
60/711,289 25 August 2005 (25.08.2005) US

(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; Sodertalje, S-SE-151 85
(SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GREEN, Larry L.
[US/US]; 464 Hill Street, San Francisco, California 94114
(US). ZHOU, Qing [US/US]; 1106 Starfish Terrace, Fre-
mont, California 94536 (US). KEYT, Bruce, A. [US/US];
1180 Lakeview Drive, Hillsborough, California 94010
(US). YANG, Xiao-dong [US/US]; 2833 Bryant Street,
Palo Alto, California 94306 (US). EMERY, Stephen,
Charles [GB/GB]; ASTRAZENECA R & D ALDERLEY,
Alderley Park, Macclesfield Cheshire SK 10 4TG (GB).
BLAKEY, David C. [GB/GB]; ASTRAZENECA R & D
ALDERLEY, Alderley Park, Macclesfield Cheshire SK
10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
2 August 2007

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF



(57) Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human mon-
oclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and
light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning
the framework regions and/or complementary determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through
CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

WO 2006/068953 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/045657

A. CLASSIFICATION OF SUBJECT MATTER INV. C07K16/22 C07K16/28 C12N15/13 C12N15/85 C12N5/10 A61K39/395 A61P35/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07K A61P A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/030833 A (AMGEN INC; OLINER, JOHNATHAN, DANIEL) 17 April 2003 (2003-04-17) page 88, lines 2-9; tables 8,9 page 84, paragraph B figure 2c; example 5 page 64, lines 3-5 ----- -/--	1-40
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 1 June 2006		Date of mailing of the international search report 22/06/2006
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Siaterli, M-Z

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/045657

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIN PENGNIAN ET AL: "Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 100, no. 8, 1997, pages 2072-2078, XP002294946 ISSN: 0021-9738 cited in the application	26-28,30
Y	page 2073, left-hand column, paragraph 1 - right-hand column, paragraph 2 page 2076, left-hand column, paragraph 2 page 2077, right-hand column, last paragraph	1-25,29, 31-40
X	OLINER J ET AL: "Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2" CANCER CELL, XX, US, vol. 6, no. 5, November 2004 (2004-11), pages 507-516, XP002348738 ISSN: 1535-6108 page 508, right-hand column, paragraph 2; figures 1,2; table 1	1-40
X	WO 00/75323 A (IMMUNEX CORPORATION; CERRETTI, DOUGLAS, P; BORGES, LUIS, G; FANSLOW, W) 14 December 2000 (2000-12-14)	26-32
Y	examples 1,7	1-25, 33-40
A	MAISONPIERRE P C ET AL: "ANGIOPOIETIN-2, A NATURAL ANTAGONIST FOR TIE2 THAT DISRUPTS IN VIVO ANGIOGENESIS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 277, 4 July 1997 (1997-07-04), pages 55-60, XP002046280 ISSN: 0036-8075 cited in the application page 56, middle column, lines 2-4	

-/--

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2005/045657

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FIEDLER ULRIKE ET AL: "Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 17 JAN 2003, vol. 278, no. 3, 17 January 2003 (2003-01-17), pages 1721-1727, XP002383517 ISSN: 0021-9258 page 1726, right-hand column, paragraph 2</p>	
Y	<p>CAI M ET AL: "Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 309, no. 4, 3 October 2003 (2003-10-03), pages 946-951, XP004455833 ISSN: 0006-291X page 948, left-hand column, paragraph 3; table 1</p>	1-25, 29, 31-40
A	<p>ROBINSON CANDY S ET AL: "The effects of Angiopoietin-2 and neutralizing anti-TIE-2 antibody on microvessel growth, branching, and regression in the ex vivo rat aortic ring explant model of angiogenesis" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03), page 2, XP001208033 & 92ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; NEW ORLEANS, LA, USA; MARCH 24-28, 2001 ISSN: 0197-016X abstract</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2005/045657

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2005/045657

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03030833	A	17-04-2003	CA 2461435 A1	17-04-2003
			CN 1602317 A	30-03-2005
			EP 1495053 A2	12-01-2005
			JP 2005506067 T	03-03-2005
			MX PA04003345 A	08-07-2004
			NO 20041907 A	10-05-2004
			US 2003124129 A1	03-07-2003
WO 0075323	A	14-12-2000	AT 324444 T	15-05-2006
			AU 5328200 A	28-12-2000
			CA 2374851 A1	14-12-2000
			EP 1187918 A1	20-03-2002
			JP 2003501090 T	14-01-2003
			NZ 516258 A	27-02-2004